Pages that link to "Q37554449"
The following pages link to Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma (Q37554449):
Displaying 15 items.
- oncostatin M receptor (Q7092131) (← links)
- Interleukin 6 signal transducer (Q21116066) (← links)
- IL-6 pathway in the liver: From physiopathology to therapy (Q26766606) (← links)
- Current Proceedings in the Molecular Dissection of Hepatocellular Adenomas: Review and Hands-on Guide for Diagnosis (Q26781373) (← links)
- A cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesis (Q28818626) (← links)
- Intracellular signaling prevents effective blockade of oncogenic gp130 mutants by neutralizing antibodies (Q33557104) (← links)
- Hepatocellular adenoma classification: a comparative evaluation of immunohistochemistry and targeted mutational analysis. (Q36668087) (← links)
- Management of hepatic adenomatosis (Q38367721) (← links)
- Targeting JAK kinase in solid tumors: emerging opportunities and challenges (Q38485889) (← links)
- Jak1-STAT3 Signals Are Essential Effectors of the USP6/TRE17 Oncogene in Tumorigenesis (Q38756741) (← links)
- Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation. (Q39003208) (← links)
- Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis (Q48111678) (← links)
- Molecular classification of hepatocellular adenomas: impact on clinical practice (Q57301412) (← links)
- LPS-induced inflammation desensitizes hepatocytes to Fas-induced apoptosis through Stat3 activation-The effect can be reversed by ruxolitinib (Q89543041) (← links)
- Analysis of clinical significance and prospective molecular mechanism of main elements of the JAK/STAT pathway in hepatocellular carcinoma (Q93111064) (← links)